{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:51:15Z","timestamp":1793915475038,"version":"4.8.0"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010621","name":"Uniwersytet Medyczny w Lublinie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.bioorg.2023.106398","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T01:47:01Z","timestamp":1675043221000},"page":"106398","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Thiazolidin-4-one-based derivatives \u2013 Efficient tools for designing antiprotozoal agents. A review of the last decade"],"prefix":"10.1016","volume":"133","author":[{"given":"Helena","family":"Tuszewska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Szczepa\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u0142awomir","family":"Mandziuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8817-7470","authenticated-orcid":false,"given":"Nazar","family":"Trotsko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2023.106398_b0005","unstructured":"Toxoplasmosis. Fact sheets, https:\/\/www.euro.who.int\/__data\/assets\/pdf_file\/0011\/294599\/Factsheet-Toxoplasmosis-en.pdf [accessed 10 November 2022]."},{"key":"10.1016\/j.bioorg.2023.106398_b0010","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/S0020-7519(00)00124-7","article-title":"Toxoplasma gondii: from animals to humans","volume":"30","author":"Tenter","year":"2000","journal-title":"Int. J. Parasitol."},{"key":"10.1016\/j.bioorg.2023.106398_b0015","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2147\/DDDT.S60973","article-title":"Drugs in development for toxoplasmosis: advances, challenges, and current status","volume":"11","author":"Alday","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.bioorg.2023.106398_b0020","unstructured":"Trypanosomiasis, human African (sleeping sickness). https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/trypanosomiasis-human-african-(sleeping-sickness) 2022; [accessed 10 November 2022]."},{"key":"10.1016\/j.bioorg.2023.106398_b0025","unstructured":"Chagas disease (American trypanosomiasis). https:\/\/www.who.int\/health-topics\/chagas-disease#tab=tab_1 [accessed 10 November 2022]."},{"key":"10.1016\/j.bioorg.2023.106398_b0030","unstructured":"Leishmaniasis. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/leishmaniasis 2022 [accessed 10 November 2022]."},{"key":"10.1016\/j.bioorg.2023.106398_b0035","unstructured":"Malaria. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/malaria 2022; [accessed 10 November 2022]."},{"key":"10.1016\/j.bioorg.2023.106398_b0040","unstructured":"A. Chou, R.L. Austin, Entamoeba Histolytica. [Updated 2022 May 3]. Entamoeba histolytica. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; January 2022."},{"key":"10.1016\/j.bioorg.2023.106398_b0045","doi-asserted-by":"crossref","unstructured":"K.M.N. Sousa, A.C.C. Viana, S.F.F. Silva Caires, R.P. Bezerra, E.M. Sousa Junior, D.A.V. Marques, Profile of adverse events in toxoplasmosis drug therapy: a review, RSD 10 (2021) e505101321339. 10.33448\/rsd-v10i13.21339.","DOI":"10.33448\/rsd-v10i13.21339"},{"key":"10.1016\/j.bioorg.2023.106398_b0050","doi-asserted-by":"crossref","first-page":"7161","DOI":"10.1128\/AAC.02009-15","article-title":"Clinically Available Medicines Demonstrating Anti-Toxoplasma Activity","volume":"59","author":"Neville","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bioorg.2023.106398_b0055","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1191\/0960327106het653oa","article-title":"Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis)","volume":"25","author":"Castro","year":"2006","journal-title":"Hum. Exp. Toxicol."},{"key":"10.1016\/j.bioorg.2023.106398_b0060","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1073\/pnas.0711014105","article-title":"A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes","volume":"105","author":"Wilkinson","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bioorg.2023.106398_b0065","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00436-002-0799-9","article-title":"Arsenicals (melarsoprol), pentamidine and suramin in the treatment of human African trypanosomiasis","volume":"90","author":"No","year":"2003","journal-title":"Parasitol. Res."},{"key":"10.1016\/j.bioorg.2023.106398_b0070","doi-asserted-by":"crossref","first-page":"e0008458","DOI":"10.1371\/journal.pntd.0008458","article-title":"Instability of aquaglyceroporin (AQP) 2 contributes to drug resistance in Trypanosoma brucei","volume":"14","author":"Quintana","year":"2020","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.bioorg.2023.106398_b0075","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ijpddr.2015.04.002","article-title":"Chimerization at the AQP2\u2013AQP3 locus is the genetic basis of melarsoprol\u2013pentamidine cross-resistance in clinical Trypanosoma brucei gambiense isolates","volume":"5","author":"Graf","year":"2015","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"10.1016\/j.bioorg.2023.106398_b0080","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1517\/14656566.2015.973850","article-title":"An update on pharmacotherapy for leishmaniasis","volume":"16","author":"Sundar","year":"2015","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.bioorg.2023.106398_b0085","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2165\/00002018-200427010-00003","article-title":"Antimalarial Drug Toxicity","volume":"27","author":"Taylor","year":"2004","journal-title":"Drug Saf."},{"key":"10.1016\/j.bioorg.2023.106398_b0090","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.tips.2006.09.005","article-title":"Transporters involved in resistance to antimalarial drugs","volume":"27","author":"Valderramos","year":"2006","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bioorg.2023.106398_b0095","doi-asserted-by":"crossref","unstructured":"M. Gonzales, L.F. Dans, J. Sio-Aguilar, Antiamoebic drugs for treating amoebic colitis, Cochrane Database Syst. Rev. 1 (2019) CD006085. 10.1002\/14651858.CD006085.pub3.","DOI":"10.1002\/14651858.CD006085.pub3"},{"key":"10.1016\/j.bioorg.2023.106398_b0100","first-page":"115","article-title":"Drug resistance in amoebiasis","volume":"123","author":"Bansal","year":"2006","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.bioorg.2023.106398_b0105","first-page":"1299","article-title":"Efficacy of albendazole and mebendazole with or without levamisole for ascariasis and trichuriasis, Open Access Maced","volume":"7","author":"Anto","year":"2019","journal-title":"J Med. Sci."},{"key":"10.1016\/j.bioorg.2023.106398_b0110","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S1473-3099(14)70779-0","article-title":"Cysticercosis Working Group in Peru. Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial","volume":"14","author":"Garcia","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.bioorg.2023.106398_b0115","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1093\/4.4.768","article-title":"Adverse metabolic effects of antiparasitic drugs","volume":"4","author":"Katz","year":"1982","journal-title":"Rev. Infect. Dis."},{"key":"10.1016\/j.bioorg.2023.106398_b0120","doi-asserted-by":"crossref","first-page":"134","DOI":"10.2174\/1872213X13666190618124901","article-title":"Giardiasis: An Overview","volume":"13","author":"Leung","year":"2019","journal-title":"Recent Pat. Inflamm. Allergy Drug Discov."},{"key":"10.1016\/j.bioorg.2023.106398_b0125","doi-asserted-by":"crossref","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b01245","article-title":"Thiazoles, their benzofused systems, and thiazolidinone derivatives: Versatile and promising tools to combat antibiotic resistance","volume":"63","author":"Cascioferro","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106398_b0130","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jsps.2018.01.016","article-title":"Synthesis and antibacterial activity of new (2,4-dioxothiazolidin-5-yl\/ylidene) acetic acid derivatives with thiazolidine-2,4-dione, rhodanine and 2-thiohydantoin moieties","volume":"26","author":"Trotsko","year":"2018","journal-title":"Saudi Pharm. J."},{"key":"10.1016\/j.bioorg.2023.106398_b0135","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/2191-2858-1-15","article-title":"Synthesis of new pyrazolyl-2,4-thiazolidinediones as antibacterial and antifungal agents","volume":"1","author":"Aneja","year":"2011","journal-title":"Org. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2023.106398_b0140","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.3390\/molecules23051023","article-title":"Synthesis and antibacterial activity of new thiazolidine-2,4-dione-based chlorophenylthiosemicarbazone hybrids","volume":"23","author":"Trotsko","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2023.106398_b0145","first-page":"414","article-title":"Microvawe assisted synthesis of 3,5-disubstituted thiazolidine-2,4-diones with antifungal activity. Design, synthesis, virtual and in vitro antifungal screening","volume":"65","author":"Marc","year":"2017","journal-title":"Farmacia"},{"key":"10.1016\/j.bioorg.2023.106398_b0150","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s00044-010-9369-3","article-title":"3-Aryl-2-{4-[4-(2,4-dioxothiazolidin-5-ylmethyl)phenoxy]-phenyl}-acrylic acid alkyl ester: Synthesis and antihyperglycemic evaluation","volume":"20","author":"Kumar","year":"2011","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.bioorg.2023.106398_b0155","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.ejmech.2014.10.025","article-title":"Thiazolidine-2,4-diones as multi-targeted scaffold in medicinal chemistry: Potential anticancer agents","volume":"87","author":"Asati","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106398_b0160","doi-asserted-by":"crossref","unstructured":"V. Asati, S.K. Bharti, Design, synthesis and molecular modelling studies of novel thiazolidine-2,4-dione derivatives as potential anti-cancer agents, J. Mol. Struct. 1154 (2018) 406\u2013417. https:\/\/ doi: 10.1016\/j.molstruc.2017.10.077.","DOI":"10.1016\/j.molstruc.2017.10.077"},{"key":"10.1016\/j.bioorg.2023.106398_b0165","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/14756366.2017.1387543","article-title":"Synthesis and in vitro antiproliferative and antibacterial activity of new thiazolidine-2,4-dione derivatives","volume":"33","author":"Trotsko","year":"2018","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106398_b0170","first-page":"28","article-title":"Anti-inflammatory effects of novel thiazolidinone derivatives as bioactive heterocycles on RAW264.7 cells","volume":"16","author":"Ghafoori","year":"2017","journal-title":"Iran J. Allergy Asthma Immunol."},{"key":"10.1016\/j.bioorg.2023.106398_b0175","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.bmc.2008.10.032","article-title":"Design, Synthesis and Pharmacological Screening of Novel Antihypertensive Agents Using Hybrid Approach","volume":"17","author":"Bhandari","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106398_b0180","doi-asserted-by":"crossref","unstructured":"A. Sachin Saini, Synthesis and anticonvulsant studies of thiazolidinone and azetidinone derivatives from indole moiety, Drug Res. 69 (2019) 445\u2013450. https:\/\/doi: 10.1055\/a-0809-5098.","DOI":"10.1055\/a-0809-5098"},{"key":"10.1016\/j.bioorg.2023.106398_b0185","doi-asserted-by":"crossref","unstructured":"N. Trotsko, Antitubercular properties of thiazolidine-4-ones \u2014 A review, Eur. J. Med. Chem. 215 (2021) 113266. https:\/\/ doi: 10.1016\/j.ejmech.2021.113266.","DOI":"10.1016\/j.ejmech.2021.113266"},{"key":"10.1016\/j.bioorg.2023.106398_b0190","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.bioorg.2017.02.007","article-title":"Evaluation of 4-thiazolidinone derivatives as potential reverse transcriptase inhibitors against HIV-1 drug resistant strains","volume":"71","author":"Suryawanshi","year":"2017","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2023.106398_b0195","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.3390\/molecules24173029","article-title":"Synthesis and in vitro anti-Toxoplasma gondii activity of novel thiazolidin-4-one derivatives","volume":"24","author":"Trotsko","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2023.106398_b0200","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ejmech.2019.04.052","article-title":"Thiazolidinone\/thiazole based hybrids\u2014New class of antitrypanosomal agents","volume":"174","author":"Kryshchyshyn","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106398_b0205","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1016\/j.bmc.2015.03.071","article-title":"Thiazolidine-2,4-dione derivatives: programmed chemical weapons for key protein targets of various pathological conditions","volume":"23","author":"Chadna","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106398_b0210","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejmech.2013.11.017","article-title":"4-Thiazolidinones: the advances continue\u2026","volume":"72","author":"Tripathi","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106398_b0215","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.bmc.2013.01.029","article-title":"Thiazolidine-2,4-diones: progress towards multifarious applications","volume":"21","author":"Jain","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106398_b0220","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ejmech.2016.02.030","article-title":"Synthetic approaches, structure activity relationship and biological applications for pharmacologically attractive pyrazole\/pyrazoline-thiazolidine-based hybrids","volume":"113","author":"Havrylyuk","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106398_b0225","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3389\/fcimb.2018.00360","article-title":"A perspective on thiazolidinone scaffold development as a new therapeutic strategy for toxoplasmosis","volume":"8","author":"Rocha-Roa","year":"2018","journal-title":"Front Cell Infect. Microbiol"},{"key":"10.1016\/j.bioorg.2023.106398_b0230","doi-asserted-by":"crossref","unstructured":"A. Kryshchyshyn, D. Kaminskyy, P. Grellier, R. Lesyk, Thiazolidinone-related heterocyclic compounds as potential antitrypanosomal agents. In: Kuznetsov A editor. Azoles - Synthesis, properties, applications and perspectives. IntechOpen. 2020 online.","DOI":"10.5772\/intechopen.91861"},{"key":"10.1016\/j.bioorg.2023.106398_b0235","first-page":"276","article-title":"The microbicidal defenses involved in intracellular Toxoplasma gondii, Trypanosoma Cruzi and Leishmania Amazonensis elimination in the presence of semicarbazones, thiosemicarbazones, and Thiazolidinones, World","volume":"7","author":"De Carvalho","year":"2018","journal-title":"J. Pharm. Res."},{"key":"10.1016\/j.bioorg.2023.106398_b0240","doi-asserted-by":"crossref","first-page":"794","DOI":"10.4269\/ajtmh.13-0722","article-title":"Neglected parasitic infections in the United States: toxoplasmosis","volume":"90","author":"Jones","year":"2014","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.bioorg.2023.106398_b0245","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1080\/14756366.2017.1316494","article-title":"Synthesis and biological evaluation of anti-Toxoplasma gondii activity of a novel scaffold of thiazolidinone derivatives","volume":"32","author":"Carradori","year":"2017","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106398_b0250","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.3201\/eid0911.030143","article-title":"Toxoplasma gondii and schizophrenia","volume":"9","author":"Torrey","year":"2003","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.bioorg.2023.106398_b0255","doi-asserted-by":"crossref","first-page":"e0003525","DOI":"10.1371\/journal.pntd.0003525","article-title":"Toxoplasmosis and epilepsy - systematic review and meta-analysis","volume":"9","author":"Ngoungou","year":"2015","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.bioorg.2023.106398_b0260","doi-asserted-by":"crossref","unstructured":"M. Bayani, S.M. Riahi, N. Bazrafshan, H. Ray Gamble, A. Rostami, Toxoplasma gondii infection and risk of Parkinson and Alzheimer diseases: A systematic review and meta-analysis on observational studies, Acta Trop. 196 (2019) 165-171. 10.1016\/j.actatropica.2019.05.015.","DOI":"10.1016\/j.actatropica.2019.05.015"},{"key":"10.1016\/j.bioorg.2023.106398_b0265","doi-asserted-by":"crossref","first-page":"e00036","DOI":"10.1016\/j.fawpar.2019.e00036","article-title":"Treatment of toxoplasmosis: Current options and future perspectives","volume":"15","author":"Konstantinovic","year":"2019","journal-title":"Food Waterborne Parasitol."},{"key":"10.1016\/j.bioorg.2023.106398_b0270","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejmech.2014.08.046","article-title":"Design, synthesis and biological characterization of thiazolidin-4-one derivatives as promising inhibitors of Toxoplasma gondii","volume":"86","author":"D'Ascenzio","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106398_b0275","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1590\/S0100-879X2009005000038","article-title":"Anti-parasitic action and elimination of intracellular Toxoplasma gondii in the presence of novel thiosemicarbazone and its 4-thiazolidinone derivatives","volume":"43","author":"Carvalho","year":"2010","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.bioorg.2023.106398_b0280","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1016\/j.ejmech.2010.05.017","article-title":"Synthesis and evaluation of anti-Toxoplasma gondii and antimicrobial activities of thiosemicarbazides, 4-thiazolidinones and 1,3,4-thiadiazoles","volume":"45","author":"Liesen","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106398_b0285","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ijpddr.2021.05.004","article-title":"In vitro evaluation of new 4-thiazolidinones on invasion and growth of Toxoplasma gondii","volume":"16","author":"Molina","year":"2021","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"10.1016\/j.bioorg.2023.106398_b0290","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1186\/s12864-018-5223-7","article-title":"Protein targets of thiazolidinone derivatives in Toxoplasma gondii and insights into their binding to ROP18","volume":"19","author":"Molina","year":"2018","journal-title":"BMC Genomics"},{"key":"10.1016\/j.bioorg.2023.106398_b0295","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0020-7519(01)00153-9","article-title":"The life cycle of Trypanosoma cruzi revisited","volume":"31","author":"Tyler","year":"2001","journal-title":"Int. J. Parasitol."},{"key":"10.1016\/j.bioorg.2023.106398_b0300","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.pcad.2009.02.001","article-title":"Perspectives on Trypanosoma cruzi-induced heart disease (Chagas disease)","volume":"51","author":"Tanowitz","year":"2009","journal-title":"Prog. Cardiovasc. Dis."},{"key":"10.1016\/j.bioorg.2023.106398_b0305","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1586\/14787210.7.2.157","article-title":"Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities","volume":"7","author":"Viotti","year":"2009","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"10.1016\/j.bioorg.2023.106398_b0310","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.2174\/1389450120666190423160804","article-title":"Major Kinds of Drug Targets in Chagas Disease or American Trypanosomiasis","volume":"20","author":"Duschak","year":"2019","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.bioorg.2023.106398_b0315","doi-asserted-by":"crossref","unstructured":"M. Souza, M.L. de Souza, C. de Oliveira Rezende Junior, R.S. Ferreira, R.M. Espinoza Ch\u00e1vez, L.L.G. Ferreira, B.W. Slafer, L.G. Magalh\u00e3es, R. Krogh, G. Oliva, F.C. Cruz, L.C. Dias, A.D. Andricopulo, Discovery of potent, reversible, and competitive cruzain inhibitors with trypanocidal activity: A structure-based drug design approach, J. Chem. Inf. Model. 60 (2020) 1028-1041. https:\/\/doi.org\/10.1021\/acs.jcim.9b00802.","DOI":"10.1021\/acs.jcim.9b00802"},{"key":"10.1016\/j.bioorg.2023.106398_b0320","first-page":"126","article-title":"Anti-parasite effects of new Thiosemicarbazones and their products Thiazolidinones including cellular aspects of intracellular elimination of Trypanosoma cruzi in vitro","volume":"3","author":"De Carvalho","year":"2014","journal-title":"J. Develop. Drugs"},{"key":"10.1016\/j.bioorg.2023.106398_b0325","doi-asserted-by":"crossref","first-page":"7478","DOI":"10.1016\/j.bmc.2015.10.048","article-title":"Structural design, synthesis and pharmacological evaluation of 4-thiazolidinones against Trypanosoma cruzi","volume":"23","author":"De Filho","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106398_b0330","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/cmdc.201300354","article-title":"Structural design, synthesis and structure-activity relationships of thiazolidinones with enhanced anti-Trypanosoma cruzi activity","volume":"9","author":"Moreira","year":"2014","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2023.106398_b0335","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1039\/D0RA06994A","article-title":"The design, synthesis, and in vitro trypanocidal and leishmanicidal activities of 1,3-thiazole and 4-thiazolidinone ester derivatives","volume":"11","author":"Haroon","year":"2021","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2023.106398_b0340","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ijantimicag.2012.09.018","article-title":"Effect of thiazolidine LPSF SF29 on the growth and morphology of Trypanosoma cruzi","volume":"41","author":"Moreira","year":"2013","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.bioorg.2023.106398_b0345","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0924-8579(94)90012-4","article-title":"Drug used in the treatment of sleeping sickness (human African trypanosomiasis: HAT)","volume":"4","author":"W\u00e9ry","year":"1994","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.bioorg.2023.106398_b0350","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/ana.21429","article-title":"The continuing problem of human African trypanosomiasis (sleeping sickness)","volume":"64","author":"Kennedy","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bioorg.2023.106398_b0355","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ejmech.2014.07.103","article-title":"Synthesis of pyrazoline\u2013thiazolidinone hybrids with trypanocidal activity","volume":"85","author":"Havrylyuk","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106398_b0360","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.bioorg.2019.01.045","article-title":"Synthesis of 5-enamine-4-thiazolidinone derivatives with trypanocidal and anticancer activity","volume":"86","author":"Holota","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2023.106398_b0365","doi-asserted-by":"crossref","first-page":"e4385","DOI":"10.1002\/aoc.4385","article-title":"New thiazolidine-2,4-dione derivatives combined with organometallic ferrocene: Synthesis, structure and antiparasitic activity","volume":"32","author":"Oderinlo","year":"2018","journal-title":"Appl. Organometal. Chem."},{"key":"10.1016\/j.bioorg.2023.106398_b0370","unstructured":"WHO report: Leishmaniasis. https:\/\/www.who.int\/health-topics\/leishmaniasis#tab=tab_1 (accessed 10 November 2022)."},{"key":"10.1016\/j.bioorg.2023.106398_b0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mam.2016.11.012","article-title":"Leishmania infections: Molecular targets and diagnosis","volume":"57","author":"Akhoundi","year":"2017","journal-title":"Mol. Asp. Med."},{"key":"10.1016\/j.bioorg.2023.106398_b0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127616","article-title":"Assessing different thiazolidine and thiazole based compounds as antileishmanial scaffolds","volume":"30","author":"Schadich","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2023.106398_b0385","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejmech.2015.02.038","article-title":"New heterocyclic hybrids of pyrazole and its bioisosteres: design, synthesis and biological evaluation as dual acting antimalarial-antileishmanial agents","volume":"94","author":"Bekhit","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106398_b0390","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ejmech.2016.07.060","article-title":"Structure-guided discovery of thiazolidine-2,4-dione derivatives as a novel class of Leishmania major pteridine reductase 1 inhibitors","volume":"123","author":"Leite","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106398_b0395","doi-asserted-by":"crossref","unstructured":"F.S.M. Neri, D.B.C. J\u00fanior, T.Q. Froes, P.B.G. da Silva, M.S. do Egito, P.O.L. Moreira, F. de Pilla Varotti, M.S. Castilho, R.G. Teixeira-Neto, J.F.C. de Albuquerque, F.H.A. Leite, Antileishmanial activity evaluation of thiazolidine-2,4-dione against Leishmania infantum and Leishmania braziliensis, Parasitol. Res. 119 (2020) 2263-2274. 10.1007\/s00436-020-06706-3.","DOI":"10.1007\/s00436-020-06706-3"},{"key":"10.1016\/j.bioorg.2023.106398_b0400","doi-asserted-by":"crossref","first-page":"465","DOI":"10.7883\/yoken.65.465","article-title":"Evolution of Plasmodium falciparum drug resistance: implications for the development and containment of artemisinin resistance","volume":"65","author":"Mita","year":"2012","journal-title":"Jpn. J. Infect. Dis."},{"key":"10.1016\/j.bioorg.2023.106398_b0405","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3390\/microorganisms8060865","article-title":"Crossing the vacuolar rubicon: Structural insights into effector protein trafficking in apicomplexan parasites","volume":"8","author":"Egea","year":"2020","journal-title":"Microorg."},{"key":"10.1016\/j.bioorg.2023.106398_b0410","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00436-006-0313-x","article-title":"Hemozoin biocrystallization in Plasmodium falciparum and the antimalarial activity of crystallization inhibitors","volume":"100","author":"Hempelmann","year":"2007","journal-title":"Parasitol. Res."},{"key":"10.1016\/j.bioorg.2023.106398_b0415","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1016\/j.bmc.2011.06.025","article-title":"Synthesis and antimalarial activity of new heterocyclic hybrids based on chloroquine and thiazolidinone scaffolds","volume":"19","author":"Ruiz","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106398_b0420","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3109\/14756366.2012.710848","article-title":"Design and synthesis of 3-[(7-chloro-1-oxidoquinolin-4-ylamino)alkyl]-1,3-thiazolidin-4-ones as antimalarial agents","volume":"28","author":"Solomon","year":"2013","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106398_b0425","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12936-017-1755-6","article-title":"Primaquine-thiazolidinones block malaria transmission and development of the liver exoerythrocytic forms","volume":"16","author":"Aguiar","year":"2017","journal-title":"Malar. J."},{"key":"10.1016\/j.bioorg.2023.106398_b0430","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.exppara.2018.01.015","article-title":"Novel arylidene derivatives of quinoline based thiazolidinones: Synthesis, in vitro, in vivo and in silico study as antimalarials","volume":"185","author":"Jain","year":"2018","journal-title":"Exp. Parasitol."},{"key":"10.1016\/j.bioorg.2023.106398_b0435","first-page":"1236","article-title":"Novel 5-chloroindoline-2,3-dione derivatives: Synthesis, characterization and preliminary evaluation of antimalarial activity","volume":"52B","author":"Shingade","year":"2013","journal-title":"Indian J. Chem."},{"key":"10.1016\/j.bioorg.2023.106398_b0440","doi-asserted-by":"crossref","first-page":"48","DOI":"10.7124\/bc.000A20","article-title":"Preliminary evaluation of thiazolidinone- and pyrazoline-related heterocyclic derivatives as potential antimalarial agents","volume":"36","author":"Kryshchyshyn-Dylevych","year":"2020","journal-title":"Biopolym. Cell"},{"key":"10.1016\/j.bioorg.2023.106398_b0445","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.ejmech.2014.11.061","article-title":"Synthesis and structure-activity-relationship studies of thiazolidinediones as antiplasmodial inhibitors of the Plasmodium falciparum cysteine protease falcipain-2","volume":"90","author":"Sharma","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106398_b0450","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJMra022710","article-title":"Amoebiasis","volume":"348","author":"Haque","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2023.106398_b0455","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1742-7843.2004.pto940505.x","article-title":"Reproductive and cytogenetic toxicity of metronidazole in male mice","volume":"94","author":"El-Nahas","year":"2004","journal-title":"Basic Clin. Pharmacol."},{"key":"10.1016\/j.bioorg.2023.106398_b0460","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S1383-5742(02)00007-8","article-title":"Is metronidazole carcinogenic?","volume":"511","author":"Bendesky","year":"2002","journal-title":"Mutat. Res."},{"key":"10.1016\/j.bioorg.2023.106398_b0465","doi-asserted-by":"crossref","unstructured":"S. Senthilkumaran, S. Shah, N. Balamurugan, P. Thirumalaikolundusubramanian, Metronidazole encephalopathy: Uncommon reaction to a common drug, Int. J. Crit. Illn. Inj. Sci. 5 (2015) 123-124. 10.4103\/2229-5151.158422.","DOI":"10.4103\/2229-5151.158422"},{"key":"10.1016\/j.bioorg.2023.106398_b0470","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0165-1218(96)00022-5","article-title":"Genotoxic effects of metronidazole","volume":"370","author":"Elizondo","year":"1996","journal-title":"Mutat. Res."},{"key":"10.1016\/j.bioorg.2023.106398_b0475","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/00001432-200310000-00016","article-title":"Entamoeba histolytica: an update","volume":"16","author":"Stauffer","year":"2003","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.bioorg.2023.106398_b0480","first-page":"0918","article-title":"Amoebic dysentery","volume":"2011","author":"Mackey-Lawrence","year":"2011","journal-title":"BMJ Clin. Evid."},{"key":"10.1016\/j.bioorg.2023.106398_b0485","first-page":"202","article-title":"Efficacy of a single dose of secnidazole in the treatment of acute and chronic amoebiasis","volume":"91","author":"Latonio","year":"1988","journal-title":"J. Trop. Med. Hyg."},{"key":"10.1016\/j.bioorg.2023.106398_b0490","first-page":"776","article-title":"Emetine in amoebiasis","volume":"43","author":"Sinha","year":"1946","journal-title":"Antiseptic"},{"key":"10.1016\/j.bioorg.2023.106398_b0495","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/0035-9203(64)90110-5","article-title":"Dehydroemetine in acute amoebiasis","volume":"58","author":"Salem","year":"1964","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"10.1016\/j.bioorg.2023.106398_b0500","first-page":"504","article-title":"Paromomycin in the treatment of intestinal amebiasis; a short course of therapy","volume":"48","author":"Simon","year":"1967","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.bioorg.2023.106398_b0505","doi-asserted-by":"crossref","first-page":"12533","DOI":"10.1074\/jbc.M110.197376","article-title":"Structural and biochemical studies of serine acetyltransferase reveal why the parasite Entamoeba histolytica cannot form a cysteine synthase complex","volume":"286","author":"Kumar","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2023.106398_b0510","first-page":"1859","article-title":"Entamoeba histolytica thioredoxin reductase: molecular and functional characterization of its atypical properties","volume":"2012","author":"Arias","year":"1820","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bioorg.2023.106398_b0515","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejmech.2012.06.052","article-title":"Synthesis, characterization and structure optimization of a series of thiazolidinone derivatives as Entamoeba histolytica inhibitors","volume":"55","author":"Mushtaque","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106398_b0520","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ejmech.2016.08.053","article-title":"Synthesis, antiamoebic and molecular docking studies of furan-thiazolidinone hybrids","volume":"124","author":"Ansari","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2023.106398_b0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127549","article-title":"Synthesis of metronidazole based thiazolidinone analogs as promising antiamoebic agents","volume":"30","author":"Ansari","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206823000585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206823000585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:39:27Z","timestamp":1758616767000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206823000585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":105,"alternative-id":["S0045206823000585"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2023.106398","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thiazolidin-4-one-based derivatives \u2013 Efficient tools for designing antiprotozoal agents. A review of the last decade","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2023.106398","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106398"}}